A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
A putative tumor suppressor locus on the short arm of human chromosome 9 has been localized to a region of less than 40 kilobases by means of homozygous deletions in melanoma cell lines. This region contained a gene, Multiple Tumor Suppressor 1 (MTS1), that encodes a previously identified inhibitor (p16) of cyclin-dependent kinase 4. MTS1 was homozygously deleted at high frequency in cell lines derived from tumors of lung, breast, brain, bone, skin, bladder, kidney, ovary, and lymphocyte. Melanoma cell lines that carried at least one copy of MTS1 frequently carried nonsense, missense, or frameshift mutations in the gene. These findings suggest that MTS1 mutations are involved in tumor formation in a wide range of tissues.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Within months of its discovery, the INK4a (CDKN2A) and the genetically linked INK4b gene (CDKN2B) (36) were implicated in a reverse genetic screen to play tumor suppressive roles in familial melanoma (37).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [37]
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
A novel cyclin encoded by a bcl1-linked candidate oncogene
Motokura, T., Bloom, T., Kim, H. G., Jüppner., H., Ruderman, J. V., Kronenberg, H. M., & Arnold, A. (1991) · Nature · doi:10.1038/350512a0 · Cited by 1,265
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit
Gu, Y., Turck, C. W., & Morgan, D. O. (1993) · Nature · doi:10.1038/366707a0 · Cited by 764
p53: At the Crossroads of Molecular Carcinogenesis and Risk Sssessment
Harris, C. C. (1993) · Science · doi:10.1126/science.8266092 · Cited by 475
PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.
Rosenberg, C. L., Wong, E., Petty, E. M., Bale, A. E., Tsujimoto, Y., Harris, N. L., & Arnold, A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.21.9638 · Cited by 432
Research works printed but not linked: 1
- Weaver-Feldhaus, J., Proceedings of the National Academy of Sciences of the United States of America 91: 7563 (1994).
Cited by
Items 601–700 of 1,005
Pancreatic adenocarcinoma: epidemiology and genetics.
Flanders, T. Y., & Foulkes, W. D. (1996) · Journal of Medical Genetics · doi:10.1136/jmg.33.11.889 · Cited by 98
Takada, H., Imoto, I., Tsuda, H., Sonoda, I., Ichikura, T., Mochizuki, H., Okanoue, T., & Inazawa, J. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00016.x · Cited by 87
Kato, D., Miyazawa, K., Ruas, M., Starborg, M., Wada, I., Oka, T., Sakai, T., Peters, G., & Hara, E. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00426-8 · Cited by 87
CDKN2A (p16INK4A) somatic and germline mutations
Smith-Sørensen, B., & Hovig, E. (1996) · Human Mutation · doi:10.1002/(sici)1098-1004(1996)7:4<294::aid-humu2>3.0.co;2-9 · Cited by 87
APOPTOSIS OF CRYPT EPITHELIAL CELLS IN ULCERATIVE COLITIS
IWAMOTO, M., KOJI, T., MAKIYAMA, K., KOBAYASHI, N., & NAKANE, P. K. (1996) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199610)180:2<152::aid-path649>3.0.co;2-y · Cited by 312
Replicative senescence revisited.
Marcotte, R., & Wang, E. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.7.b257 · Cited by 86
Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance
Horn, S., Leonardelli, S., Sucker, A., Schadendorf, D., Griewank, K., & Paschen, A. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx271 · Cited by 87
Park, U. S., Park, S. K., Lee, Y. I., Park, J. G., & Lee, Y. I. (2000) · Oncogene · doi:10.1038/sj.onc.1203674 · Cited by 93
“CDK inhibitors can negatively regulate cell cycle progression in response to a variety of antiproliferative signals including DNA damage, di erentiation, contact inhibition and senescence (Grana and Reddy, 1995; Kamb et al., 1994).”
BackgroundExpression of p57KIP2 Potently Blocks the Growth of Human Astrocytomas and Induces Cell Senescence
Tsugu, A., Sakai, K., Dirks, P. B., Jung, S., Weksberg, R., Fei, Y. L., Mondal, S., Ivanchuk, S. M., Ackerley, C. A., Hamel, P. A., et al. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64605-6 · Cited by 86
Molecular Biology of Human Oral Cancer
Wong, D. T., Todd, R., Tsuji, T., & Donoff, R. B. (1996) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/10454411960070040201 · Cited by 98
The role of transforming growth factor Β in glioma progression
Jennings, M. T., & Pietenpol, J. A. (1998) · Journal of Neuro-Oncology · doi:10.1023/a:1005863419880 · Cited by 99
Larramendy, M. L., Tarkkanen, M., BLOMQVIST, C. P., Virolainen, M. J., Wiklund, T. A., Asko-Seljavaara, S. L., Elomaa, I., & Knuutila, S. (1997) · Europe PMC (PubMed Central) · Cited by 100
Kashiwabara, K., Oyama, T., Sano, T., Fukuda, T., & Nakajima, T. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980619)79:3<232::aid-ijc4>3.0.co;2-q · Cited by 85
Phelps, D. E., Hsiao, K.-M., Li, Y., Hu, N., Franklin, D. S., Westphal, E., Lee, E. Y.-H. P., & Xiong, Y. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.4.2334 · Cited by 86
“p16 represents the other family of CDK inhibitors that includes three additionally isolated genes: p15 (also known as MTS2 and p14) (8, 12, 17), p18 (8), and p19 (2, 9, 14).”
BackgroundRole of p27 in Prostate Carcinogenesis
Macrì, E., & Loda, M. F. (1998) · Cancer and Metastasis Reviews · doi:10.1023/a:1006133620914 · Cited by 86
“Mutation and deletions, or inactivation by methylation of pl6 and p15 genes, have been reported in various human malignancies and transformed cell lines [ 3 ].”
BackgroundTranscriptional analysis of the PTEN/MMAC1 pseudogene, ΨPTEN
Fujii, G. H., Morimoto, A. M., Berson, A. E., & Bolen, J. B. (1999) · Oncogene · doi:10.1038/sj.onc.1202492 · Cited by 84
“These observations raise the possibility that chromosome 9 may contain tumor suppressors in addition to p16 (Cairns et al., 1995; Cheng et al., 1994; Kamb et al., 1994; Merlo et al., 1995).”
BackgroundMolecular Analysis of the 9p21 Locus and p53 Genes in Ewing Family Tumors
López‐Guerrero, J. A., Pellín, A., Noguera, R., Cardá, C., & Llombart‐Bosch, A. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780290 · Cited by 89
“Among these CDKI are p16INK4A (MTS1, CDKN2) (Kamb et al, 1994; Serrano et al, 1993) and p15INK4B (MTS2) (Hannon and Beach, 1994), which form binary complexes exclu- sively with CDK4 and CDK6, inhibiting their function and, by so doing, inhibiting pRb phosphorylation during G1 (Graña and Reddy, 1995; Huschtscha and Red…”
BackgroundInfluentialCell cycle profiles and expressions of p21CIP1 and p27KIP1 during myocyte development
Poolman, R. A., Gilchrist, R., & Brooks, G. (1998) · International Journal of Cardiology · doi:10.1016/s0167-5273(98)00320-9 · Cited by 93
Role of the RB Tumor Suppressor in Cancer
Yamasaki, L. (2006) · Cancer Treatment and Research · doi:10.1007/0-306-48158-8_9 · Cited by 84
Second-generation interferons for cancer: clinical targets
Borden, E. C., Lindner, D. J., Dreicer, R., Hussein, M. A., & Peereboom, D. M. (2000) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0315 · Cited by 96
P53 Gene Mutations in Lymphoid Diseases and Their Possible Relevance to Drug Resistance
Newcomb, E. W. (1995) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199509056825 · Cited by 97
Kohno, T., Otsuka, A., Girard, L., Sato, M., Iwakawa, R., Ogiwara, H., Sánchez‐Céspedes, M., Minna, J. D., & Yokota, J. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20746 · Cited by 95
“, 2002; Yokota and Kohno, 2004), and has played an important role as a tool in identifying several tumor suppressor genes, such as CDKN2A/ p16, PTEN, and SMAD4 (Kamb et al., 1994; Nobori et al., 1994; Hahn et al., 1996; Li et al., 1997; Steck et al., 1997).”
BackgroundInfluentialWittekindt, C., G�ltekin, E., Weissenborn, S. J., Dienes, H. P., Pfister, H., & Klußmann, J. P. (2004) · KARGER eBooks · doi:10.1159/000082474 · Cited by 97
Kim, J. S., Kim, J. W., Han, J., Shim, Y. M., Park, J., & Kim, D.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3813 · Cited by 84
The p16INK4a tumor suppressor controls p21WAF1 induction in response to ultraviolet light
Almohanna, M., Al‐Khalaf, H. H., Al‐Yousef, N., & Aboussekhra, A. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl1075 · Cited by 92
Müllerian Inhibiting Substance Inhibits Ovarian Cell Growth through an Rb-independent Mechanism
Ha, T. U., Segev, D. L., Barbie, D. A., Masiakos, P. T., Tran, T. T., Dombkowski, D., Glander, M., Clarke, T. R., Lorenzo, H. K., Donahoe, P. K., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005701200 · Cited by 98
Furumoto, K., Arii, S., Yamasaki, S., Mizumoto, M., Mori, A., Inoue, N., Isobe, N., & Imamura, M. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000901)87:5<680::aid-ijc10>3.0.co;2-p · Cited by 52
Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus
Park, W., Vortmeyer, A. O., Pack, S., Duray, P. H., Böni, R., Guerami, A. A., Emmert‐Buck, M. R., Liotta, L. A., & Zhuang, Z. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90221-0 · Cited by 87
Modulation of Cell Cycle Components by Epigenetic and Genetic Events
Macaluso, M., Montanari, M., Cinti, C., & Giordano, A. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.07.009 · Cited by 95
Deregulated expression of p27(Kip1) in human breast cancers.
Sgambato, A., Zhang, Y. J., Arber, N., Hibshoosh, H. H., Doki, Y., Ciaparrone, M., Santella, R. M., Cittadini, A. R. M., & Weinstein, I. B. (1997) · PubMed · Cited by 95
Two tumor suppressive loci on chromosome 10 involved in human glioblastomas
Steck, P. A., Ligon, A. H., Cheong, P. Y. Y., Yung, W. K. A., & Pershouse, M. A. (1995) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870120404 · Cited by 84
Aberrations of the G1- and G1/S-regulating genes in human cancer
Bártková, J., Lukas, J., & Bártek, J. (1997) · Springer eBooks · doi:10.1007/978-1-4615-5371-7_16 · Cited by 100
Ohnishi, H., Kawamura, M., Ida, K., Sheng, X., Hanada, R., Nobori, T., Yamamori, S., & Hayashi, Y. (1995) · Blood · doi:10.1182/blood.v86.4.1269.bloodjournal8641269 · Cited by 84
Inactivation of p16INK4a expression in malignant mesothelioma by methylation
Wong, L., Zhou, J. X., Anderson, D., & Kratzke, R. A. (2002) · Lung Cancer · doi:10.1016/s0169-5002(02)00178-2 · Cited by 90
Liang, J.-T., Chang, K.-J., Chen, J.-C., Lee, C.-C., Cheng, Y.-M., Hsu, H.-C., Wu, M.-S., Wang, S.-M., Lin, J.-T., & Cheng, A.-L. (1999) · Oncology · doi:10.1159/000012023 · Cited by 83
“In humans, the p16 gene is located at 9p21 and is composed of three exons, which encode a 156-amino-acid, 15.8-kD protein that blocks progression through the cell cycle by binding to either cyclin-dependent kinase (CDK) 4 or 6 and inhibiting the action of cyclin D [”
BackgroundInfluentialOverexpression of Cyclin‐dependent Kinase‐activating CDC25B Phosphatase in Human Gastric Carcinomas
Kudo, Y., Yasui, W., Ue, T., Yamamoto, S., Yokozaki, H., Nikai, H., & Tahara, E. (1997) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1997.tb00313.x · Cited by 91
Rieger, K. M., Little, A. F., Swart, J., Kastrinakis, W. V., Fitzgerald, J., Hess, D. T., Libertino, J., & Summerhayes, I. C. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.394 · Cited by 83
Smits, R., Hofland, N., Edelmann, W., Geugien, M., Jagmohan-Changur, S., Albuquerque, C., Breukel, C., Kucherlapati, R., Kielman, M. F., & Fodde, R. (2000) · Genes, Chromosomes and Cancer · doi:10.1002/1098-2264(2000)9999:9999<::aid-gcc1033>3.0.co;2-r · Cited by 91
Zhang, A., Feng, H., Yang, G., Pan, X., Jiang, X., Huang, X., Dong, X.-X., Da-ping, Y., Xie, Y., Luo, P., et al. (2007) · Environmental Health Perspectives · doi:10.1289/ehp.9272 · Cited by 83
Gildea, J. J., Golden, W. L., Harding, M. A., & Theodorescu, D. (2000) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(200003)27:3<323::aid-gcc14>3.0.co;2-p · Cited by 78
Meningiomas: Updating Basic Science, Management, and Outcome
Drummond, K. J., Zhu, J., & Black, P. M. (2004) · The Neurologist · doi:10.1097/01.nrl.0000126588.14216.f3 · Cited by 88
Wassberg, C., Thörn, M., Yuen, J., Ringborg, U. K., & Hakulinen, T. R. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.45 · Cited by 87
A Unique Domain of pRb2/p130 Acts as an Inhibitor of Cdk2 Kinase Activity
Luca, A. D., MacLachlan, T. K., Bagella, L., Dean, C., Howard, C. M., Claudio, P. P., Baldi, A., Khalili, K., & Giordano, A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.20971 · Cited by 90
Larramendy, M. L., Tarkkanen, M., Valle, J., Kivioja, A., Ervasti, H., Karaharju, E., Salmivalli, T., Elomaa, I., & Knuutila, S. (1997) · Europe PMC (PubMed Central) · Cited by 82
Olopade, O. I., Pomykala, H. M., Hagos, F., Sveen, L. W., Espinosa, R., Dreyling, M. H., Gursky, S., Stadler, W. M., Le Beau, M. M., & Bohlander, S. K. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6489 · Cited by 82
Allelotype analysis of childhood acute lymphoblastic leukemia.
Takeuchi, S., Bartram, C. R., Wada, M., Reiter, A., Hatta, Y., Seriu, T., Lee, E., Miller, C. W., Miyoshi, I., & Koeffler, H. (1995) · PubMed · Cited by 82
Fears, S. C., Vignon, C., Bohlander, S. K., Smith, S. D., Rowley, J. D., & Nucifora, G. (1996) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199610)17:2<127::aid-gcc8>3.0.co;2-7 · Cited by 59
Mirzayans, R., Andrais, B., Hansen, G., & Murray, D. (2012) · Biochemistry Research International · doi:10.1155/2012/951574 · Cited by 81
INK4 cell cycle inhibitors direct transcriptional inactivation of NF-κB
Wolff, B., & Naumann, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202617 · Cited by 85
“…in oncogenesis (reviewed in Luque and Gelinas, 1997), likewise frequent genetic alterations and functional inhibition of p16 in human tumors (Kamb et al., 1994; Lukas et al., 1995) and especially in pancreatic tumors (Caldas et al., 1994; Naumann et al., 1996) have suggested that its…”
BackgroundPromoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas
Yoshino, A., Katayama, Y., Ogino, A., Watanabe, T., Yachi, K., Ohta, T., Komine, C., Yokoyama, T., & Fukushima, T. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9316-9 · Cited by 87
“also been confirmed as one of the tumor suppressor genes in human tumors [4, 5, 26 ].”
BackgroundGenetic and Molecular Markers of Urothelial Premalignancy and Malignancy
Cordon‐Cardo, C., Côté, R. J., & Sauter, G. (2000) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/003655900750169338 · Cited by 83
The INK4A/ARF Locus: Role in Cell Cycle Control and Apoptosis and Implications for Glioma Growth
Ivanchuk, S. M., Mondal, S., Dirks, P. B., & Rutka, J. T. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1010632309113 · Cited by 93
“It was discovered as a gene at the 9p21 chromosomal locus by positional cloning in efforts to locate a familial melanoma susceptibility gene [3].”
BackgroundMyc and E2F1 induce p53 through p14ARF-independent mechanisms in human fibroblasts
Lindström, M. S., & Wiman, K. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206659 · Cited by 94
“This locus also encodes the cyclin-dependent kinase inhibitor p16INK4a (Kamb et al., 1994).”
BackgroundHow does interferon exert its cell growth inhibitory effect?
Grandér, D., Sangfelt, O., & Erickson, S. (1997) · European Journal of Haematology · doi:10.1111/j.1600-0609.1997.tb00965.x · Cited by 81
Genetic changes in epithelial solid neoplasia.
Rodrı́guez, E., Sreekantaiah, C., & Chaganti, R. S. K. (1994) · PubMed · Cited by 81
Peters, G. G. (1994) · Nature · doi:10.1038/371204a0 · Cited by 88
Lesnikova, I., Lidang, M., Hamilton-Dutoit, S. J., & Koch, J. (2009) · Diagnostic Pathology · doi:10.1186/1746-1596-4-22 · Cited by 91
Henshall, S. M., Quinn, D. I., Lee, C. S., Head, D. R., Golovsky, D., Brenner, P. C., Delprado, W., Stricker, P. D., Grygiel, J. J., & Sutherland, R. L. (2001) · Macquarie University · Cited by 90
Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma
Zhao, P., Hu, Y.-C., & Talbot, I. C. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i10.2202 · Cited by 83
Molecular Pathogenesis of Pituitary Tumors
Farrell, W. E., & Clayton, R. N. (2000) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1999.0195 · Cited by 84
Sánchez‐Beato, M., Sáez, A. I., Navas, I. C., Algara, P., Mateo, M. S., Villuendas, R., Camacho, F. I., Sánchez‐Aguilera, A., Sánchez, E., & Piris, M. A. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61686-0 · Cited by 89
Puig, S., Ruiz, A., Lázaro, C., CASTEL, T., Lynch, M., Palou, J., Vilalta, A., Weissenbach, J., Mascaró, J. M., & Estivill, X. (1995) · Europe PMC (PubMed Central) · Cited by 95
Genetic analysis of cellular senescence
Vojta, P. J., & Barrett, J. C. (1995) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00002-w · Cited by 95
Homozygous deletions of human chromosome 3p in lung tumors.
Todd, S., Franklin, W. A., Varella-Garcia, M., Kennedy, T., Hilliker, C., Hahner, L., Anderson, M. W., Wiest, J. S., Drabkin, H. A., & Gemmill, R. M. (1997) · PubMed · Cited by 80
Mutation screening of theCDKN2A promoter in melanoma families
Harland, M., Holland, E. A., Ghiorzo, P., Mantelli, M., Bianchi-Scarr�, G., Goldstein, A. M., Tucker, M. A., Ponder, B. A. J., Mann, G. J., Bishop, D. T., et al. (2000) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(200005)28:1<45::aid-gcc6>3.0.co;2-f · Cited by 73
Flørenes, V. A., Lü, C., Bhattacharya, N., Rak, J. W., Sheehan, C., Slingerland, J. M., & Kerbel, R. S. (1999) · Oncogene · doi:10.1038/sj.onc.1202382 · Cited by 84
“…owing to the observation that it is frequently mutated, deleted, or transcriptionally repressed in human tumors and tumor derived cell lines (Kamb et al., 1994a; Nobori et al., 1994; Caldas et al., 1994; Spruck et al., 1994), in familial melanoma (Kamb et al., 1994b) and, to a lesser…”
BackgroundFrequent mutations of CDKN2 in primary pancreatic adenocarcinomas
Bartsch, D., Shevlin, D. W., Tung, W. S., Kisker, O., Wells, S. A., & Goodfellow, P. J. (1995) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870140306 · Cited by 79
Maloney, K. W., McGavran, L., Odom, L. F., & Hunger, S. P. (1999) · Blood · doi:10.1182/blood.v93.7.2380 · Cited by 79
REPORT on the Third International Workshop on Chromosome 9
Povey, S., Armour, J. A. L., Farndon, P. A., Haines, J. L., Knowles, M. A., OLOPADE, F., Pilz, A. J., & Kwiatkowski, D. J. (1994) · Annals of Human Genetics · doi:10.1111/j.1469-1809.1994.tb01887.x · Cited by 83
Yosry, A. (2006) · KARGER eBooks · doi:10.1159/000092967 · Cited by 77
p16 expression in primary malignant melanoma is associated with prognosis and lymph node status
Mihic‐Probst, D., Mnich, C. D., Oberholzer, P. A., Seifert, B., Sasse, B., Moch, H., & Dummer, R. (2005) · International Journal of Cancer · doi:10.1002/ijc.21608 · Cited by 85
Genetic insights into familial tumors of the nervous system
Melean, G., Sestini, R., Ammannati, F., & Papi, L. (2004) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30022 · Cited by 93
“…were mapped: CDKN2A, which encodes the p16INK4A and p14ARF proteins, through the use of an alternative exon 1 (1b), and CDKN2B, coding for p15 [Kamb et al., 1994; Stone et al., 1995]. p16INK4A is encoded by three exons [exons 1a, 2, and 3], whereas p14ARF is encoded by the alternative exon…”
BackgroundPalanca-Wessels, M. C., Barrett, M. T., Galipeau, P. C., Rohrer, K. L., Reid, B. J., & Rabinovitch, P. S. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70480-9 · Cited by 67
High prevalence of p16 genetic alterations in head and neck tumours
Miracca, E. C., Kowalski, L. P., & Nagai, M. A. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690747 · Cited by 81
“p2 ina us ne s sm en an rta ran dk e ma g t a et –22, ygous et al, ous l lines cer, e , in a The oreas, ldas et 996; ediset al, ss of 9 ddi- High prevalence of p16 genetic alterations in head and neck tumours”
BackgroundGenetic Alterations ofp16INK4aandp53Genes in Sporadic Dysplastic Nevus
Lee, J. Y., Dong, S. M., Shin, M. S., Kim, S. Y., Lee, S. H., Kang, S. J., Lee, J. D., Kim, C. S., Kim, S. H., & Yoo, N. J. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7212 · Cited by 84
CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers
Bertoni, F., Codegoni, A. M., Furlan, D., Tibiletti, M. G., Capella, C., & Broggini, M. (1999) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199910)26:2<176::aid-gcc11>3.0.co;2-3 · Cited by 121
Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract.
Igaki, H., Sasaki, H., Tachimori, Y., Kato, H., Watanabe, H., Kimura, T., Harada, Y., Sügimura, T., & Terada, M. (1995) · PubMed · Cited by 78
Human papillomavirus-related head and neck tumors: clinical and research implication
Psyrri, A. K., Gouveris, P., & Vermorken, J. B. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328329ab64 · Cited by 77
Molecular biology of adenoid cystic carcinoma
Liu, J., Shao, C., Tan, M., Mu, D., Ferris, R. L., & Ha, P. K. (2011) · Head & Neck · doi:10.1002/hed.21849 · Cited by 80
Frequent Loss of Chromosome Arms 8p and 13q in Collecting Duct Carcinoma (CDC) of the Kidney
Schoenberg, M., Brooks, J. D., Marshall, F. F., Epstein, J. I., Isaacs, W. B., Cairns, P., & Sidransky, D. (1995) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870120115 · Cited by 77
Mechanism of Retinoblastoma Gene Inactivation in the Spectrum of Neuroendocrine Lung Tumors
Gouyer, V., Gazzéri, S., Bolon, I., Drevet, C., Brambilla, C., & Brambilla, E. (1998) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.18.2.3008 · Cited by 78
“Although mutations in exons 13 to 18 and 20 to 24 of the RB gene leading to the expression of an Rb protein with altered function have been described, such mutations are rare (44, 45), and we found that p16INK4 was inactivated in the majority of these cases (data not shown) suggesting a normal RB function.”
BackgroundInfluentialLinkage of the grey coat colour locus to microsatellites on horse chromosome 25
Locke, M. M., Penedo, M. C. T., Bricker, S. J., Millon, L. V., & Murray, J. D. (2002) · Animal Genetics · doi:10.1046/j.1365-2052.2002.00885.x · Cited by 77
Malignant pleural mesothelioma
Pass, H. I., Vogelzang, N. J., Hahn, S. M., & Carbone, M. (2004) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2004.04.001 · Cited by 79
Genetic Epidemiology of Familial Melanoma
Goldstein, A. M., & Tucker, M. A. (1995) · Dermatologic Clinics · doi:10.1016/s0733-8635(18)30066-4 · Cited by 86
Cross, N. C. P. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb08403.x · Cited by 79
Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL)
Hatta, Y., & Koeffler, H. (2002) · Leukemia · doi:10.1038/sj.leu.2402458 · Cited by 90
Dual role of MEK/ERK signaling in senescence and transformation of intestinal epithelial cells
Boucher, M.-J., Jean, D., Vézina, A., & Rivard, N. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00453.2003 · Cited by 76
Genetics of Uveal Melanoma and Cutaneous Melanoma: Two of a Kind?
van den Bosch, T., Kılıç, E., Paridaens, D. A., & de Klein, A. (2010) · Dermatology Research and Practice · doi:10.1155/2010/360136 · Cited by 83
“CDKN2A-familial deletion, mutation 9p21 30–80 [88–91]”
BackgroundMolecular biology of laryngeal squamous cell carcinoma
Nadal, A., & Cardesa, A. (2003) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-002-0726-6 · Cited by 77
“p16INK4a can be inactivated by a variety of mechanisms such as mutation, homozygous deletion [ 36 ], and promoter hypermethylation that leads to gene silencing [45].”
BackgroundTsai, K. Y., & Tsao, H. (2004) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30037 · Cited by 87
“…of a number of melanoma prone kindreds, employing cytogenetic and LOH analyzes, led to the identifica- tion of the CDKN2A/MTS1 locus on chromosome 9p21 as the susceptibility locus for familial melanoma [Cannon- Albright et al., 1992; Fountain et al., 1992; Kamb et al., 1994; Nobori et al., 1994].”
MethodPines, J. (1994) · Nature · doi:10.1038/369520a0 · Cited by 80
Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma
Corson, J. M. (1995) · Lung Cancer · doi:10.1016/0169-5002(96)84216-4 · Cited by 76
“min. Hybridization was with PI clones 1063 and 1069 ( 11 ), which comprise a 100-kb contig including both pl5 and /;/f).”
BackgroundMethodInfluentialGenetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects
Griewank, K., Scolyer, R. A., Thompson, J. F., Flaherty, K. T., Schadendorf, D., & Murali, R. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt435 · Cited by 84
CDK/CCN and CDKI Alterations for Cancer Prognosis and Therapeutic Predictivity
Bonelli, P., Tuccillo, F. M., Borrelli, A., Schiattarella, A., & Buonaguro, F. M. (2014) · BioMed Research International · doi:10.1155/2014/361020 · Cited by 82
“Oncogenic alterations of CCNs, CDKs, CDKIs, and other components of Rb pathway have been reported in more than 90% of human cancers [1, 2, 17–40] as summarized in Table 1.”
BackgroundNelson, A. A., & Tsao, H. (2008) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2008.09.005 · Cited by 109
Kikuchi, R., Tsuda, H., Kanai, Y., Kasamatsu, T., Sengoku, K., Hirohashi, S., Inazawa, J., & Imoto, I. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4567 · Cited by 68
Differential Roles of p16INK4A and p14ARF Genes in Prognosis of Oral Carcinoma
Sailasree, R., Abhilash, A. J. B., Sathyan, K. M., Nalinakumari, K. R., Thomas, S., & Kannan, S. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0284 · Cited by 84
“Loss of p16 in the Rb pathway releases the inhibition on CCND1/cdk complex, which in turn phosphorylates Rb, leading to cell cycle progression (16).”
BackgroundBilateral Primary Uveal Melanoma
Singh, A. D., Shields, C. L., Shields, J. A., & Potter, P. D. (1996) · Ophthalmology · doi:10.1016/s0161-6420(96)30707-0 · Cited by 87
Molecular pathogenesis and prognostic factors in endometrial carcinoma
Salvesen, H. B., & Akslen, L. A. (2002) · Apmis · doi:10.1034/j.1600-0463.2002.1101001.x · Cited by 79
“It encodes for the p16 protein found to bind specifically to the cyclin-dependent kinase CDK4, inhibiting the catalytic activity of the CDK4-cyclin D complex, acting as a negative cell cycle regulator (41).”
BackgroundMoller, H., & Skakkebæk, N. E. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960503)66:3<287::aid-ijc2>3.0.co;2-v · Cited by 192
Metadata
- Authors
- Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H.
- Affiliations
- Myriad Genetics (US)
- Memorial Sloan Kettering Cancer Center (US)
- Cross Cancer Institute (CA)
- National Institutes of Health (US)
- University of Utah (US)
- Venue
- Science
- Published
- 1994-04-15
- Volume
- 264
- Issue
- 5157
- Pages
- 436-440
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1983348452
- Cited by
- 2,751
- References
- 26
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 18 · 2023: 12 · 2022: 22 · 2021: 31 · 2020: 24 · 2019: 23 · 2018: 34 · 2017: 45 · 2016: 20 · 2015: 32 · 2014: 31 · 2013: 44 · 2012: 54
- FWCI
- 115.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ca048711-05)
- National Cancer Institute (CA 48711)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDKN2A, p16, tumor suppressor, chromosome 9p, homozygous deletion, melanoma cell lines, CDK4, cell cycle regulation, genetic mutations
- MeSH terms
- Base Sequence, Carrier Proteins, Cell Cycle, Chromosomes, Human, Pair 9, Cosmids, Exons, Humans, Introns, Melanoma, Molecular Sequence Data, Mutation, Neoplasms, Proto-Oncogene Proteins, Tumor Cells, Cultured, Genes, Tumor Suppressor, Gene Deletion, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase Inhibitor p16, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.